AKARI Therapeutics Company

Akari is developing inhibitors of acute and chronic inflammation, specifically the complement and leukotriene systems, to treat rare and orphan diseases with unmet need.


Connections from

Funding Status: IPO
Headquarters: United States
Founded Date: 2005
Investor Type: N/A
Investment Stage: N/A
Technology: Scientifically-Validated Lifestyle Recommendation
Employee Number: 11-50
Number Of Exists: N/A
Industry: Stem Cell Exhaustion